https://stock.noler.com/us/stock/gene-biotherapeutics-inc https://stock.noler.com/us/stock/gene-biotherapeutics-inc/accounts-payable https://stock.noler.com/us/stock/gene-biotherapeutics-inc/accounts-payable-trade-current-and-noncurrent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/accounts-receivable https://stock.noler.com/us/stock/gene-biotherapeutics-inc/accounts-receivable-gross-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/accrued-employee-benefits-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/accrued-liabilities-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/accrued-salaries-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/accumulated-depreciation https://stock.noler.com/us/stock/gene-biotherapeutics-inc/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/gene-biotherapeutics-inc/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/gene-biotherapeutics-inc/additional-paid-in-capital https://stock.noler.com/us/stock/gene-biotherapeutics-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/gene-biotherapeutics-inc/adjustment-of-warrants-granted-for-services https://stock.noler.com/us/stock/gene-biotherapeutics-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/gene-biotherapeutics-inc/amended-reports-10-k https://stock.noler.com/us/stock/gene-biotherapeutics-inc/amended-reports-10-k405 https://stock.noler.com/us/stock/gene-biotherapeutics-inc/amended-reports-10-q https://stock.noler.com/us/stock/gene-biotherapeutics-inc/amortization https://stock.noler.com/us/stock/gene-biotherapeutics-inc/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/gene-biotherapeutics-inc/amortization-of-financing-costs https://stock.noler.com/us/stock/gene-biotherapeutics-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/gene-biotherapeutics-inc/area-of-land https://stock.noler.com/us/stock/gene-biotherapeutics-inc/asset-impairment-charges https://stock.noler.com/us/stock/gene-biotherapeutics-inc/assets-noncurrent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/assets-of-disposal-group-including-discontinued-operation-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/assets-of-disposal-group-including-discontinued-operation-noncurrent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/basic-shares https://stock.noler.com/us/stock/gene-biotherapeutics-inc/business-acquisition-equity-interests-issued-or-issuable-number-of-shares-issued https://stock.noler.com/us/stock/gene-biotherapeutics-inc/business-acquisitions-pro-forma-net-income-loss https://stock.noler.com/us/stock/gene-biotherapeutics-inc/capital-expenditures https://stock.noler.com/us/stock/gene-biotherapeutics-inc/cash https://stock.noler.com/us/stock/gene-biotherapeutics-inc/cash-acquired-from-acquisition https://stock.noler.com/us/stock/gene-biotherapeutics-inc/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/gene-biotherapeutics-inc/cash-and-equivalents https://stock.noler.com/us/stock/gene-biotherapeutics-inc/cash-and-restricted-cash-including-disposal-group-and-discontinued-operations https://stock.noler.com/us/stock/gene-biotherapeutics-inc/cash-fdic-insured-amount https://stock.noler.com/us/stock/gene-biotherapeutics-inc/cash-flow-breakdown https://stock.noler.com/us/stock/gene-biotherapeutics-inc/class-of-warrant-or-right-exercise-price-of-warrants-or-rights https://stock.noler.com/us/stock/gene-biotherapeutics-inc/class-of-warrant-or-right-number-of-securities-called-by-warrants-or-rights https://stock.noler.com/us/stock/gene-biotherapeutics-inc/class-of-warrant-or-right-outstanding https://stock.noler.com/us/stock/gene-biotherapeutics-inc/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/gene-biotherapeutics-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/gene-biotherapeutics-inc/common-stock-share-subscribed-but-unissued-subscriptions-receivable https://stock.noler.com/us/stock/gene-biotherapeutics-inc/common-stock-shares-subscriptions https://stock.noler.com/us/stock/gene-biotherapeutics-inc/common-stock-value https://stock.noler.com/us/stock/gene-biotherapeutics-inc/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/gene-biotherapeutics-inc/convertible-preferred-stock-shares-issued-upon-conversion https://stock.noler.com/us/stock/gene-biotherapeutics-inc/cost-of-goods-sold-depreciation-and-amortization https://stock.noler.com/us/stock/gene-biotherapeutics-inc/cost-of-revenue https://stock.noler.com/us/stock/gene-biotherapeutics-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/gene-biotherapeutics-inc/current-assets https://stock.noler.com/us/stock/gene-biotherapeutics-inc/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/current-liabilities https://stock.noler.com/us/stock/gene-biotherapeutics-inc/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/debt-decrease-forgiveness https://stock.noler.com/us/stock/gene-biotherapeutics-inc/debt-interest-rate-stated-percentage https://stock.noler.com/us/stock/gene-biotherapeutics-inc/debt-issued https://stock.noler.com/us/stock/gene-biotherapeutics-inc/debt-repaid https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-federal-income-tax-expense-benefit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-rent-credit-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-rent-credit-noncurrent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-state-and-local-income-tax-expense-benefit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-tax-credit-carryforwards-research https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-tax-deferred-expense https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-tax-deferred-expense-compensation-and-benefits https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-accrued-liabilities https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-deferred-rent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-impairment-losses https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/gene-biotherapeutics-inc/deposits-assets-noncurrent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/depreciation https://stock.noler.com/us/stock/gene-biotherapeutics-inc/depreciation-and-amortization https://stock.noler.com/us/stock/gene-biotherapeutics-inc/depreciation-and-amortization-discontinued-operations https://stock.noler.com/us/stock/gene-biotherapeutics-inc/derivative-financial-instruments-liabilities-fair-value-disclosure https://stock.noler.com/us/stock/gene-biotherapeutics-inc/derivative-liabilities-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/diluted-shares https://stock.noler.com/us/stock/gene-biotherapeutics-inc/discontinued-operation-gain-loss-from-disposal-of-discontinued-operation-before-income-tax https://stock.noler.com/us/stock/gene-biotherapeutics-inc/discontinued-operation-gain-loss-on-disposal-of-discontinued-operation-net-of-tax https://stock.noler.com/us/stock/gene-biotherapeutics-inc/discontinued-operation-income-loss-from-discontinued-operation-during-phase-out-period-before-income-tax https://stock.noler.com/us/stock/gene-biotherapeutics-inc/due-to-officers-or-stockholders-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/due-to-officers-or-stockholders-current-and-noncurrent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/gene-biotherapeutics-inc/effective-tax-rate https://stock.noler.com/us/stock/gene-biotherapeutics-inc/eps https://stock.noler.com/us/stock/gene-biotherapeutics-inc/eps-basic https://stock.noler.com/us/stock/gene-biotherapeutics-inc/equity-issuance-per-share-amount https://stock.noler.com/us/stock/gene-biotherapeutics-inc/equity-method-investment-ownership-percentage https://stock.noler.com/us/stock/gene-biotherapeutics-inc/escrow-deposit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/fair-value-adjustment-of-warrants https://stock.noler.com/us/stock/gene-biotherapeutics-inc/fair-value-inputs-discount-rate https://stock.noler.com/us/stock/gene-biotherapeutics-inc/fair-value-of-assets-acquired https://stock.noler.com/us/stock/gene-biotherapeutics-inc/financing-cash-flow https://stock.noler.com/us/stock/gene-biotherapeutics-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/gene-biotherapeutics-inc/finite-lived-intangible-assets-amortization-expense-after-year-five https://stock.noler.com/us/stock/gene-biotherapeutics-inc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/gene-biotherapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/gene-biotherapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/gene-biotherapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/gene-biotherapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/gene-biotherapeutics-inc/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/gene-biotherapeutics-inc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/gene-biotherapeutics-inc/form-d-other https://stock.noler.com/us/stock/gene-biotherapeutics-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/gene-biotherapeutics-inc/gain-loss-on-sale-of-business https://stock.noler.com/us/stock/gene-biotherapeutics-inc/gain-loss-on-sale-of-leased-assets-net-operating-leases https://stock.noler.com/us/stock/gene-biotherapeutics-inc/gain-loss-on-sales-of-assets-and-asset-impairment-charges https://stock.noler.com/us/stock/gene-biotherapeutics-inc/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/gene-biotherapeutics-inc/general-and-administrative-expense https://stock.noler.com/us/stock/gene-biotherapeutics-inc/goodwill https://stock.noler.com/us/stock/gene-biotherapeutics-inc/grants-receivable https://stock.noler.com/us/stock/gene-biotherapeutics-inc/gross-profit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/impairment-of-intangible-assets-finitelived https://stock.noler.com/us/stock/gene-biotherapeutics-inc/impairment-of-investments https://stock.noler.com/us/stock/gene-biotherapeutics-inc/impairment-of-long-lived-assets-held-for-use https://stock.noler.com/us/stock/gene-biotherapeutics-inc/income-loss-from https://stock.noler.com/us/stock/gene-biotherapeutics-inc/income-loss-from-discontinued-operations-net-of-tax-attributable-to-reporting-entity https://stock.noler.com/us/stock/gene-biotherapeutics-inc/income-loss-from-discontinued-operations-net-of-tax-per-basic-and-diluted-share https://stock.noler.com/us/stock/gene-biotherapeutics-inc/income-loss-from-per-basic-and-diluted-share https://stock.noler.com/us/stock/gene-biotherapeutics-inc/income-tax https://stock.noler.com/us/stock/gene-biotherapeutics-inc/income-tax-examination-liability-refund-adjustment-from-settlement-with-taxing-authority https://stock.noler.com/us/stock/gene-biotherapeutics-inc/income-tax-examination-penalties-and-interest-expense https://stock.noler.com/us/stock/gene-biotherapeutics-inc/income-tax-expense-benefit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/income-taxes-paid https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-cash-collateral-for-loaned-securities https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-deferred-liabilities https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-deferred-rent-receivables https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-deposit-other-assets https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-deposits https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-inventories https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-other-noncurrent-assets https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/gene-biotherapeutics-inc/increase-decrease-in-security-deposits https://stock.noler.com/us/stock/gene-biotherapeutics-inc/incremental-common-shares-attributable-to-call-options-and-warrants https://stock.noler.com/us/stock/gene-biotherapeutics-inc/incremental-common-shares-attributable-to-conversion-of-preferred-stock https://stock.noler.com/us/stock/gene-biotherapeutics-inc/indefinite-lived-intangible-assets-written-off-related-to-sale-of-business-unit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/indefinite-lived-license-agreements https://stock.noler.com/us/stock/gene-biotherapeutics-inc/insider-transactions-preferred https://stock.noler.com/us/stock/gene-biotherapeutics-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/gene-biotherapeutics-inc/insider-transactions-warrants https://stock.noler.com/us/stock/gene-biotherapeutics-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/gene-biotherapeutics-inc/interest-expense https://stock.noler.com/us/stock/gene-biotherapeutics-inc/interest-paid https://stock.noler.com/us/stock/gene-biotherapeutics-inc/interest-paid-net https://stock.noler.com/us/stock/gene-biotherapeutics-inc/inventory https://stock.noler.com/us/stock/gene-biotherapeutics-inc/inventory-adjustments https://stock.noler.com/us/stock/gene-biotherapeutics-inc/inventory-finished-goods https://stock.noler.com/us/stock/gene-biotherapeutics-inc/inventory-gross https://stock.noler.com/us/stock/gene-biotherapeutics-inc/inventory-raw-materials https://stock.noler.com/us/stock/gene-biotherapeutics-inc/inventory-valuation-reserves https://stock.noler.com/us/stock/gene-biotherapeutics-inc/inventory-write-down https://stock.noler.com/us/stock/gene-biotherapeutics-inc/investing-cash-flow https://stock.noler.com/us/stock/gene-biotherapeutics-inc/investment-income-interest https://stock.noler.com/us/stock/gene-biotherapeutics-inc/investments-fair-value-disclosure https://stock.noler.com/us/stock/gene-biotherapeutics-inc/issuance-of-stock-and-warrants-for-services-or-claims https://stock.noler.com/us/stock/gene-biotherapeutics-inc/late-filing-notices-nt-10-k https://stock.noler.com/us/stock/gene-biotherapeutics-inc/late-filing-notices-nt-10-q https://stock.noler.com/us/stock/gene-biotherapeutics-inc/lease-and-rental-expense https://stock.noler.com/us/stock/gene-biotherapeutics-inc/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/gene-biotherapeutics-inc/level-3-asset-change https://stock.noler.com/us/stock/gene-biotherapeutics-inc/level-3-asset-value https://stock.noler.com/us/stock/gene-biotherapeutics-inc/liabilities-of-disposal-group-including-discontinued-operation-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/long-term-investments https://stock.noler.com/us/stock/gene-biotherapeutics-inc/long-term-notes-payable https://stock.noler.com/us/stock/gene-biotherapeutics-inc/marketing-and-advertising-expense https://stock.noler.com/us/stock/gene-biotherapeutics-inc/minority-interest https://stock.noler.com/us/stock/gene-biotherapeutics-inc/net-cash-from-financing-activities https://stock.noler.com/us/stock/gene-biotherapeutics-inc/net-cash-from-investing-activities https://stock.noler.com/us/stock/gene-biotherapeutics-inc/net-cash-from-operating-activities https://stock.noler.com/us/stock/gene-biotherapeutics-inc/net-change-in-cash https://stock.noler.com/us/stock/gene-biotherapeutics-inc/net-income https://stock.noler.com/us/stock/gene-biotherapeutics-inc/net-income-loss-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/gene-biotherapeutics-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/gene-biotherapeutics-inc/noncash-or-part-noncash-acquisition-accounts-receivable-acquired https://stock.noler.com/us/stock/gene-biotherapeutics-inc/noncash-or-part-noncash-acquisition-fixed-assets-acquired https://stock.noler.com/us/stock/gene-biotherapeutics-inc/noncash-or-part-noncash-acquisition-inventory-acquired https://stock.noler.com/us/stock/gene-biotherapeutics-inc/noncash-or-part-noncash-acquisition-noncash-financial-or-equity-instrument-consideration-shares-issued https://stock.noler.com/us/stock/gene-biotherapeutics-inc/noncash-or-part-noncash-acquisition-other-liabilities-assumed https://stock.noler.com/us/stock/gene-biotherapeutics-inc/noncash-or-part-noncash-acquisition-payables-assumed https://stock.noler.com/us/stock/gene-biotherapeutics-inc/noncash-or-part-noncash-acquisition-value-of-assets-acquired https://stock.noler.com/us/stock/gene-biotherapeutics-inc/noncash-or-part-noncash-acquisition-value-of-liabilities-assumed https://stock.noler.com/us/stock/gene-biotherapeutics-inc/noncash-or-part-noncash-divestiture-amount-of-consideration-received https://stock.noler.com/us/stock/gene-biotherapeutics-inc/notes-issued https://stock.noler.com/us/stock/gene-biotherapeutics-inc/notes-payable-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/number-of-operating-segments https://stock.noler.com/us/stock/gene-biotherapeutics-inc/number-of-reportable-segments https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-cash-flow https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-expenses https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-income https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-assets https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-liability https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-liability-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-payments-due https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-payments-due-2 https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-leases-rent-expense-net https://stock.noler.com/us/stock/gene-biotherapeutics-inc/operating-loss-carryforwards https://stock.noler.com/us/stock/gene-biotherapeutics-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/other-assets https://stock.noler.com/us/stock/gene-biotherapeutics-inc/other-income https://stock.noler.com/us/stock/gene-biotherapeutics-inc/other-noncurrent-assets https://stock.noler.com/us/stock/gene-biotherapeutics-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/gene-biotherapeutics-inc/other-restricted-assets-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/gene-biotherapeutics-inc/paid-in-capital-warrant-issued https://stock.noler.com/us/stock/gene-biotherapeutics-inc/payments-for-rent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/payments-of-debt-issuance-costs https://stock.noler.com/us/stock/gene-biotherapeutics-inc/payments-of-financing-costs https://stock.noler.com/us/stock/gene-biotherapeutics-inc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/gene-biotherapeutics-inc/payments-to-acquire-in-process-research-and-development https://stock.noler.com/us/stock/gene-biotherapeutics-inc/pledged-financial-instruments-not-separately-reported-securities-pledged https://stock.noler.com/us/stock/gene-biotherapeutics-inc/preferred-shares-facts https://stock.noler.com/us/stock/gene-biotherapeutics-inc/preferred-stock-dividends-and-other-adjustments https://stock.noler.com/us/stock/gene-biotherapeutics-inc/preferred-stock-dividends-income-statement-impact https://stock.noler.com/us/stock/gene-biotherapeutics-inc/preferred-stock-shares-subscribed-but-unissued-subscriptions-receivable https://stock.noler.com/us/stock/gene-biotherapeutics-inc/preferred-stock-shares-subscribed-but-unissued-value https://stock.noler.com/us/stock/gene-biotherapeutics-inc/preferred-stock-value-outstanding https://stock.noler.com/us/stock/gene-biotherapeutics-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-divestiture-of-businesses https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-issuance-of-convertible-preferred-stock https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-issuance-of-preferred-stock-and-preference-stock https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-issuance-or-sale-of-equity https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-long-term-lines-of-credit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-notes-payable https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-other-debt https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-related-party-debt https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-repayments-of-notes-payable https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-repayments-of-related-party-debt https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-sale-of-interest-in-corporate-unit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-sale-of-productive-assets https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/gene-biotherapeutics-inc/proceeds-from-warrant-exercises https://stock.noler.com/us/stock/gene-biotherapeutics-inc/profit-loss https://stock.noler.com/us/stock/gene-biotherapeutics-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/gene-biotherapeutics-inc/property-plant-equipment https://stock.noler.com/us/stock/gene-biotherapeutics-inc/provision-for-doubtful-accounts https://stock.noler.com/us/stock/gene-biotherapeutics-inc/public-float https://stock.noler.com/us/stock/gene-biotherapeutics-inc/related-party-transaction-expenses-from-transactions-with-related-party https://stock.noler.com/us/stock/gene-biotherapeutics-inc/repayments-of-notes-payable https://stock.noler.com/us/stock/gene-biotherapeutics-inc/repayments-of-related-party-debt https://stock.noler.com/us/stock/gene-biotherapeutics-inc/research-and-development https://stock.noler.com/us/stock/gene-biotherapeutics-inc/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/gene-biotherapeutics-inc/restricted-cash-and-cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/gene-biotherapeutics-inc/restricted-cash-and-cash-equivalents-noncurrent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/restricted-investments-current https://stock.noler.com/us/stock/gene-biotherapeutics-inc/retained-earnings https://stock.noler.com/us/stock/gene-biotherapeutics-inc/revenue https://stock.noler.com/us/stock/gene-biotherapeutics-inc/revenue-from-grants https://stock.noler.com/us/stock/gene-biotherapeutics-inc/revenue-recognition-sales-returns-reserve-for-sales-returns https://stock.noler.com/us/stock/gene-biotherapeutics-inc/right-of-use-asset-obtained-in-exchange-for-operating-lease-liability https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sales-revenue-goods-net https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-comment-letters-corresp https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-comment-letters-upload https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-10-k https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-10-q https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-10ksb https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-10qsb https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-25 https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-8-a12b https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-8-a12g https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-8-k https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-certamx https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-def-14a https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-def-14c https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-defa14a https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-pre-14a https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-prer14a https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-regdex https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-revoked https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sec-filings-sb-2 https://stock.noler.com/us/stock/gene-biotherapeutics-inc/secondary-offerings-form-424b3 https://stock.noler.com/us/stock/gene-biotherapeutics-inc/secondary-offerings-form-424b5 https://stock.noler.com/us/stock/gene-biotherapeutics-inc/secondary-offerings-form-effect https://stock.noler.com/us/stock/gene-biotherapeutics-inc/secondary-offerings-form-pos-am https://stock.noler.com/us/stock/gene-biotherapeutics-inc/secondary-offerings-form-rw https://stock.noler.com/us/stock/gene-biotherapeutics-inc/secondary-offerings-form-s-1 https://stock.noler.com/us/stock/gene-biotherapeutics-inc/secondary-offerings-form-s-3 https://stock.noler.com/us/stock/gene-biotherapeutics-inc/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/gene-biotherapeutics-inc/secondary-offerings-form-s-8-pos https://stock.noler.com/us/stock/gene-biotherapeutics-inc/security-deposit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/segment-reporting-information-revenue https://stock.noler.com/us/stock/gene-biotherapeutics-inc/sga-expense https://stock.noler.com/us/stock/gene-biotherapeutics-inc/share-price https://stock.noler.com/us/stock/gene-biotherapeutics-inc/shareholders-equity https://stock.noler.com/us/stock/gene-biotherapeutics-inc/shares-authorized https://stock.noler.com/us/stock/gene-biotherapeutics-inc/shares-issued https://stock.noler.com/us/stock/gene-biotherapeutics-inc/shares-issued-shares-issued-for-services https://stock.noler.com/us/stock/gene-biotherapeutics-inc/shares-issued-shares-new-issues https://stock.noler.com/us/stock/gene-biotherapeutics-inc/shares-issued-value-issued-for-services https://stock.noler.com/us/stock/gene-biotherapeutics-inc/significant-change-in-utb-is-reasonably-possible-amount-of-unrecorded-benefit https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-award-fair-value-assumptions-expected-dividend-payments https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-award-number-of-shares-available-for-grant https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-award-options-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-based-compensation https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-compensation-unrecognized-cost https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-issued-shares-issued-shares-issued-for-cash https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-issued-shares-issued-value-conversion-of-units https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-issued-shares-issued-value-issued-for-cash https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-issued-value-of-shares-issued-for-acquisitions https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-options-expirations-in-period https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-options-nonvested-options-forfeited-grant-date-fair-value https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-options-nonvested-options-forfeited-number-of-shares https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stockholders-equity-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/gene-biotherapeutics-inc/stockholders-equity-note-changes-in-capital-structure-subsequent-changes-to-number-of-common-shares https://stock.noler.com/us/stock/gene-biotherapeutics-inc/straight-line-rent https://stock.noler.com/us/stock/gene-biotherapeutics-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/gene-biotherapeutics-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/gene-biotherapeutics-inc/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/gene-biotherapeutics-inc/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/gene-biotherapeutics-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/gene-biotherapeutics-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/gene-biotherapeutics-inc/tax-rate-reconciliation-tax-credits https://stock.noler.com/us/stock/gene-biotherapeutics-inc/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/gene-biotherapeutics-inc/tax-reconciliation-nondeductible-expense-research-and-development https://stock.noler.com/us/stock/gene-biotherapeutics-inc/technology-services-costs https://stock.noler.com/us/stock/gene-biotherapeutics-inc/total-assets https://stock.noler.com/us/stock/gene-biotherapeutics-inc/total-liabilities https://stock.noler.com/us/stock/gene-biotherapeutics-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/gene-biotherapeutics-inc/treasury-stock-value https://stock.noler.com/us/stock/gene-biotherapeutics-inc/unrealized-gain-loss-on-derivatives https://stock.noler.com/us/stock/gene-biotherapeutics-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/gene-biotherapeutics-inc/utb-income-tax-penalties-and-interest-expense https://stock.noler.com/us/stock/gene-biotherapeutics-inc/utb-resulting-in-net-operating-loss-carryforward https://stock.noler.com/us/stock/gene-biotherapeutics-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/gene-biotherapeutics-inc/warrants-not-settleable-in-cash-fair-value-disclosure https://stock.noler.com/us/stock/gene-biotherapeutics-inc/weighted-average-number-of-share-outstanding-basic-and-diluted